<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HEPARIN SODIUM- heparin sodiumÂ injectionÂ </strong><br>West-ward Pharmaceutical Corp.<br></p></div>
<h1><span class="Bold">Heparin Sodium Injection, USP</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b0dcb870-5e13-40b2-8f31-011b529219d5"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx onlyÂ </span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_b23bd96c-f6f5-4798-a3ae-ec5532bace24"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, having anticoagulant properties. Although others may be present, the main sugars occurring in heparin are: (1) Î±-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-Î±-D-glucose 6-sulfate, (3) Î²-D-glucuronic acid, (4) 2-acetamido-2-deoxy-Î±-D-glucose and (5) Î±-L-iduronic acid. These sugars are present in decreasing amounts, usually in the order (2)&gt;(1)&gt;(4)&gt;(3)&gt;(5), and are joined by glycosidic linkages, forming polymers of varying sizes. Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions.</p>
<p>Structural formula of Heparin Sodium (representative sub-units):</p>
<div class="Figure"><img alt="Structural formula of Heparin Sodium (representative sub-units)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7014808d-cec9-4b2c-8eb5-940493e356ab&amp;name=heparin-sodium-injection-usp-1.jpg"></div>
<p>Heparin Sodium Injection, USP is a sterile solution of heparin sodium derived from porcine intestinal mucosa, standardized for anticoagulant activity. It is to be administered by intravenous or deep subcutaneous routes. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.</p>
<p>Heparin Sodium Injection, USP is available in the following concentrations/mL:</p>
<table>
<col>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule" align="center">Â Heparin Sodium</td>
<td class="Botrule" align="center">Â Sodium Chloride</td>
<td class="Botrule" align="center">Â Benzyl Alcohol</td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center">Â 1,000 USP units</td>
<td align="center">Â 8.6Â mg</td>
<td align="center">Â 0.01Â mL</td>
</tr>
<tr>
<td align="center">Â 5,000 USP units</td>
<td align="center">Â 7Â mg</td>
<td align="center">Â 0.01Â mL</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">Â 10,000 USP units</td>
<td class="Botrule" align="center">Â 5Â mg</td>
<td class="Botrule" align="center">Â 0.01Â mL</td>
</tr>
</tbody>
</table>
<p>pHÂ 5.0-7.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_e1085ab6-e626-4ba3-8eed-a6c2b0ec5d53"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span>. Heparin acts at multiple sites in the normal coagulation system. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> by inactivating activated Factor X and inhibiting the conversion of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> to thrombin. Once active <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.</p>
<p><span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding time</span> is usually unaffected by heparin. Clotting time is prolonged by full therapeutic doses of heparin; in most cases, it is not measurably affected by low doses of heparin.</p>
<p>Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin times</span> (APTTs) compared with patients under 60 years of age.</p>
<p>Peak plasma levels of heparin are achieved 2 to 4 hours following subcutaneous administration, although there are considerable individual variations. Loglinear plots of heparin plasma concentrations with time, for a wide range of dose levels, are linear, which suggests the absence of zero order processes. Liver and the reticuloendothelial system are the sites of biotransformation. The biphasic elimination curve, a rapidly declining alpha phase (t<span class="Sub">1/2</span>=10 min.) and after the age of 40 a slower beta phase, indicates uptake in organs. The absence of a relationship between anticoagulant half-life and concentration half-life may reflect factors such as protein binding of heparin.</p>
<p>Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_cc42652b-be65-4f70-ba82-0ab32560e898"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Heparin Sodium Injection is indicated for:</p>
<p>Anticoagulant therapy in prophylaxis and treatment of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and its extension;</p>
<p>Low-dose regimen for prevention of postoperative deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see <span class="Bold"><a href="#LINK_3372be9d-ef64-419d-9298-19fbd2c7b323">DOSAGE AND ADMINISTRATION</a></span>);</p>
<p>Prophylaxis and treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>;</p>
<p><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> with embolization;</p>
<p>Treatment of acute and chronic consumptive coagulopathies (<span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>);</p>
<p>Prevention of clotting in arterial and cardiac surgery;</p>
<p>Prophylaxis and treatment of peripheral arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>.</p>
<p>Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_33a53ff3-eef3-4e70-b998-b03b391fe2fe"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Heparin sodium should NOT be used in patients with the following conditions:</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>;</p>
<p>When suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin);</p>
<p>An uncontrolled active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> state (see <span class="Bold"><a href="#LINK_e5d281db-df71-4928-b910-51e0983dade8">WARNINGS</a></span>), except when this is due to <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_f81171b0-5829-489f-a87c-22f115dfa065"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Heparin is not intended for intramuscular use.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a9cae1ca-990b-4695-ba45-76423cbccea0"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">Fatal Medication Errors</span></h2>
<p class="First">Do not use Heparin Sodium Injection as a â€œcatheter lock flushâ€? product. Heparin Sodium Injection is supplied in vials containing various strengths of heparin, including vials that contain a highly concentrated solution of 10,000 units in 1 mL. Fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> have occurred in pediatric patients due to medication errors in which 1 mL Heparin Sodium Injection vials were <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with 1 mL â€œcatheter lock flushâ€? vials. Carefully examine all Heparin Sodium Injection vials to confirm the correct vial choice prior to administration of the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a5b360e6-b4e5-4af0-950e-3e5404f6aa1e"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Benzyl Alcohol Toxicity</span></h2>
<p class="First">Use preservative-free Heparin Sodium Injection in neonates and infants. The preservative benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients. The minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth weight infants may be more likely to develop toxicity (see <span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">PRECAUTIONS</a></span><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">, </a><span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">Pediatric Use</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_17423e82-ae6b-4c34-9274-f00b531e96ea"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></h2>
<p class="First">Patients with documented <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to heparin should be given the drug only in clearly life-threatening situations. (See <span class="Bold"><a href="#LINK_721fcf74-8142-4a91-bc17-7af86e2b5f14">ADVERSE REACTIONS, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8e75ae1f-a9d1-4845-a429-fd223a8c268a"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> can occur at virtually any site in patients receiving heparin. An unexplained <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hematocrit, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.</p>
<p>Heparin sodium should be used with extreme caution in disease states in which there is increased danger of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Some of the conditions in which increased danger of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> exists are:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d56d8cf7-c2d8-4632-90c7-7f9e50df84b0"></a><a name="section-6.4.1"></a><p></p>
<h3>Cardiovascular</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4249899" conceptname="Subacute bacterial endocarditis">Subacute bacterial endocarditis</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_daeb5ade-50a7-44c7-a601-e451c0ddebbb"></a><a name="section-6.4.2"></a><p></p>
<h3>Surgical</h3>
<p class="First">During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord, or eye.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_56c44067-1aea-4058-bb4c-dd32bb75d785"></a><a name="section-6.4.3"></a><p></p>
<h3>Hematologic</h3>
<p class="First">Conditions associated with increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies, such as <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and some vascular <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpuras</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1d135fb3-44bc-41b0-aab5-5d0200712f58"></a><a name="section-6.4.4"></a><p></p>
<h3>Gastrointestinal</h3>
<p class="First">Ulcerative lesions and continuous tube drainage of the stomach or small intestine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_651fd8d6-22ca-4547-aca1-d2f95d56cbe9"></a><a name="section-6.4.5"></a><p></p>
<h3>Other</h3>
<p class="First">Menstruation, liver disease with impaired hemostasis.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_00109514-c8cb-4908-ae1b-afaff7678751"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Coagulation Testing</span></h2>
<p class="First">When heparin sodium is administered in therapeutic amounts, its dosage should be regulated by frequent blood coagulation tests. If the coagulation test is unduly prolonged or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> occurs, heparin sodium should be promptly discontinued. (See <span class="Bold"><a href="#LINK_1c3e48fb-10f8-4a57-9049-81a8460f9ac1">OVERDOSAGE</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c1700a30-c854-43d3-955f-1390ae83c73f"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has been reported to occur in patients receiving heparin with a reported incidence of up to 30%. Platelet counts should be obtained at baseline and periodically during heparin administration. Mild <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (count greater than 100,000/mm<span class="Sup">3</span>) may remain stable or reverse even if heparin is continued. However, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> of any degree should be monitored closely. If the count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100,000/mm<span class="Sup">3</span> or if recurrent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> develops (see <span class="Bold"><a href="#LINK_e363f66e-6a5b-40dd-b332-6ed4bed6ad38"><span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced Thrombocytopenia</span> (HIT) With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span></a></span>), the heparin product should be discontinued and, if necessary, an alternative anticoagulant administered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9715e521-ab2c-4e74-8e7b-45a68054a0f0"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced Thrombocytopenia</span> (HIT) (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>)</span></h2>
<p class="First">HIT is a serious immune-mediated reaction resulting from irreversible aggregation of platelets. HIT may progress to the development of venous and arterial thromboses, a condition referred to as HIT with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. Thrombotic events may also be the initial presentation for HIT. These serious <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> include <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, cerebral vein <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, limb <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, renal <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span>, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> of the extremities that may lead to amputation, and fatal outcomes.</p>
<p>Once HIT (with or without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>) is diagnosed or strongly suspected, all heparin sodium sources (including heparin flushes) should be discontinued and an alternative anticoagulant used.Â  Future use of heparin sodium, especially within 3 to 6 months following the diagnosis of HIT (with or without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>), and while patients test positive for HIT antibodies, should be avoided.</p>
<p>Immune-mediated HIT is diagnosed based on clinical findings supplemented by laboratory tests confirming the presence of antibodies to heparin sodium, or platelet activation induced by heparin sodium. A drop in platelet count greater than 50% from baseline is considered indicative of HIT. Platelet counts begin to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> 5 to 10 days after exposure to heparin sodium in heparin sodium-naÃ¯ve individuals, and reach a threshold by days 7 to 14. In contrast, â€œrapid onsetâ€? HIT can occur very quickly (within 24 hours following heparin sodium initiation), especially in patients with a recent exposure to heparin sodium (i.e., previous 3 months). <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> development shortly after documenting <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> is a characteristic finding in almost half of all patients with HIT.</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> of any degree should be monitored closely. If the platelet count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100,000/mm<span class="Sup">3</span> or if recurrent <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> develops, the heparin product should be promptly discontinued and alternative anticoagulants considered if patients require continued anticoagulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_52b191a5-e4c9-4100-82a1-77e0aeb52798"></a><a name="section-6.8"></a><p></p>
<h2><span class="Bold">Delayed Onset of HIT (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>)</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced Thrombocytopenia</span> (with or without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>) can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> after discontinuation of heparin sodium should be evaluated for HIT (with or without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1bb9578b-4df7-4209-8527-e492009249df"></a><a name="section-6.9"></a><p></p>
<h2><span class="Bold">Use in Neonates</span></h2>
<p class="First">This product contains the preservative benzyl alcohol and is not recommended for use in neonates. There have been reports of fatal â€˜<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndromeâ€™ in neonates (children less than one month of age) following the administration of intravenous solutions containing the preservative benzyl alcohol. Symptoms include a striking onset of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respiration, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p>Carefully examine all Heparin Sodium Injection vials to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with â€œcatheter lock flushâ€? vials. (See <span class="Bold"><a href="#LINK_3f23bc81-ce92-4e17-80f2-c6c113b91dab">WARNINGS, Fatal Medication Errors</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_0b2e3e54-9496-495d-9bee-78c8bb455bb7"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_9ab43d28-8c9a-4149-b3fa-57a91eae01d8"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced Thrombocytopenia</span> (HIT) (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>) and Delayed Onset of HIT (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>.)</p>
<p>See <span class="Bold"><a href="#LINK_e5d281db-df71-4928-b910-51e0983dade8">WARNINGS</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f4515efb-53f2-4813-b2e4-0918acb36420"></a><a name="section-7.1.1"></a><p></p>
<h3>Heparin Resistance</h3>
<p class="First">Increased resistance to heparin is frequently encountered in <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with thrombosing tendencies, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cancer and in postsurgical patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_08b4435b-af8d-48f2-a16d-bdeab859daa6"></a><a name="section-7.1.2"></a><p></p>
<h3>Increased Risk to Older Patients, Especially Women</h3>
<p class="First">A higher incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in patients, particularly women, over 60 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_12f6be43-2c6d-4a58-a736-f9fa218a099c"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Laboratory Tests</span></h2>
<p class="First">Periodic platelet counts, hematocrits, and tests for occult <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stool</span> are recommended during the entire course of heparin therapy, regardless of the route of administration. (See <span class="Bold"><a href="#LINK_3372be9d-ef64-419d-9298-19fbd2c7b323">DOSAGE AND ADMINISTRATION</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_6dd6858e-eaef-40c4-bbb2-99809df605cf"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7660f987-d2e6-4920-b2de-bb12e61fce9c"></a><a name="section-7.3.1"></a><p></p>
<h3>Oral Anticoagulants</h3>
<p class="First">Heparin sodium may prolong the one-stage <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn, if a valid <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is to be obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_449abe4a-7461-4b5d-bf97-27772e07820c"></a><a name="section-7.3.2"></a><p></p>
<h3>Platelet Inhibitors</h3>
<p class="First">Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and should be used with caution in patients receiving heparin sodium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8c460880-ec8b-442c-8f7c-4e631eb8e15e"></a><a name="section-7.3.3"></a><p></p>
<h3>Other Interactions</h3>
<p class="First">Digitalis, tetracyclines, nicotine or antihistamines may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_1ee8c8c7-c04f-4612-ba96-cda9a511dc2d"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Tests Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_86168dff-a1ea-4fac-8e1c-e2d1700e1674"></a><a name="section-7.4.1"></a><p></p>
<h3>Hyperaminotransferasemia</h3>
<p class="First">Significant elevations of aminotransferase (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin. Since aminotransferase determinations are important in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, liver disease and pulmonary emboli, increases that might be caused by drugs (like heparin) should be interpreted with caution.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_ca1a70f5-92ff-4834-b97a-e9c6fad2c696"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to evaluate carcinogenic potential of heparin. Also, no reproduction studies in animals have been performed concerning mutagenesis or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_5f0da9a9-fc55-4f85-94d9-c71e1c0753b4"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1b7a9e70-d91f-4e2e-9041-192734ff49f2"></a><a name="section-7.6.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">There are no adequate and well-controlled studies on heparin use in pregnant women. In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. Heparin sodium does not cross the placenta based on human and animal studies. Administration of heparin to pregnant animals at doses higher than the maximum human daily dose based on body weight resulted in increased resorptions. Use heparin sodium during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>If available, preservative-free Heparin Sodium Injection is recommended when heparin therapy is needed during pregnancy. There are no known adverse outcomes associated with fetal exposure to the preservative benzyl alcohol through maternal drug administration; however, the preservative benzyl alcohol can cause serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered intravenously to neonates and infants (see <span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">PRECAUTIONS</a></span><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">, </a><span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">Pediatric Use</a></span>).</p>
<p>In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 units/kg/day, approximately 10 times the maximum human daily dose based on body weight. The number of early resorptions increased in both species. There was no evidence of teratogenic effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_2825493a-1557-47af-85fe-e66f3e1ffa29"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">If available, preservative-free Heparin Sodium Injection is recommended when heparin therapy is needed during lactation. Due to its large molecular weight, heparin is not likelyÂ to be excreted in human milk, and any heparin in milk would not be orally absorbed by a nursing infant. Benzyl alcohol present in maternal serum is likely to cross into human milk and may be orally absorbed by a nursing infant. Exercise caution when administering Heparin Sodium Injection to a nursing mother (see <span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">PRECAUTIONS, Pediatric Use</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_45320c83-be87-4768-a06b-a02fead70db7"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience (see <span class="Bold"><a href="#LINK_41e85100-eb03-4c8c-bb85-a30d127829b6">DOSAGE AND ADMINISTRATION, Pediatric Use</a></span>).</p>
<p>Carefully examine all Heparin Sodium Injection vials to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with â€œcatheter lock flushâ€? vials (see <span class="Bold"><a href="#LINK_a9cae1ca-990b-4695-ba45-76423cbccea0">WARNINGS, Fatal Medication Errors</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a988d996-23d1-413a-b578-7d8767f561a5"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">Benzyl Alcohol Toxicity</span></h2>
<p class="First">Use preservative-free Heparin Sodium Injection in neonates and infants. The preservative benzyl alcohol has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in pediatric patients. The â€œgasping syndromeâ€? (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates and low-birth weight infants. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>.</p>
<p>Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the â€œgasping syndromeâ€?, the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth weight infants may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_9e20ba79-fc59-4747-885a-e8aff35b6c74"></a><a name="section-7.10"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">A higher incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in patients over 60 years of age, especially women (see <span class="Bold"><a href="#LINK_d61aea0d-7c00-4113-9ab7-0fdc14c982dd">PRECAUTIONS, General</a></span>). Clinical studies indicate that lower doses of heparin may be indicated in these patients (see <span class="Bold"><a href="#LINK_95a8083d-258c-4f82-98b8-590a9dcc2bad">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#LINK_3372be9d-ef64-419d-9298-19fbd2c7b323">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6611e59a-ffb3-4e3f-983d-c2c1c63936ee"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fdd8d3a8-9424-48ce-9600-a21355f26d47"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> is the chief complication that may result from heparin therapy. (See <span class="Bold"><a href="#LINK_e5d281db-df71-4928-b910-51e0983dade8">WARNINGS</a></span>.) An overly prolonged clotting time or minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during therapy can usually be controlled by withdrawing the drug. (See <span class="Bold"><a href="#LINK_1c3e48fb-10f8-4a57-9049-81a8460f9ac1">OVERDOSAGE</a></span>.) <span class="Bold">It should be appreciated that gastrointestinal or urinary tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during anticoagulant therapy may indicate the presence of an underlying occult lesion.</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can occur at any site but certain specific hemorrhagic complications may be difficult to detect:</p>
<ol class="LittleAlpha">
<li><span class="product-label-link" type="condition" conceptid="4173897" conceptname="Adrenal hemorrhage">Adrenal hemorrhage</span>, with resultant acute <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>, has occurred during anticoagulant therapy. Therefore, such treatment should be discontinued in patients who develop signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="4173897" conceptname="Adrenal hemorrhage">adrenal hemorrhage</span> and insufficiency. Initiation of corrective therapy should not depend on laboratory confirmation of the diagnosis, since any delay in an acute situation may result in the patientâ€™s <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</li>
<li>Ovarian (corpus luteum) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy. This complication, if unrecognized, may be fatal.
</li>
<li><span class="product-label-link" type="condition" conceptid="4318539" conceptname="Retroperitoneal hemorrhage">Retroperitoneal hemorrhage</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5468339f-7178-4c59-9500-46e58c55784b"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-induced Thrombocytopenia</span> (HIT) (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>) and Delayed Onset of HIT (With or Without <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>).</span></h2>
<p class="First">See <span class="Bold"><a href="#LINK_e5d281db-df71-4928-b910-51e0983dade8">WARNINGS</a></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_15854e4d-839c-4a91-a04a-30c48d4fceb8"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">Local Irritation</span></h2>
<p class="First">Local irritation, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> or ulceration may follow deep subcutaneous (intrafat) injection of heparin sodium. These complications are much more common after intramuscular use, and such use is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ca4be253-a8ea-4590-9576-a1055adcd6db"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></h2>
<p class="First">Generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported, with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> as the most usual manifestations, and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>, including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, occurring more rarely. <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span> and burning, especially on the plantar side of the feet, may occur. (SeeÂ <span class="Bold"><a href="#LINK_f81171b0-5829-489f-a87c-22f115dfa065">WARNINGS</a></span> and <span class="Bold"><a href="#LINK_0b2e3e54-9496-495d-9bee-78c8bb455bb7">PRECAUTIONS</a></span>.)</p>
<p>Certain episodes of painful, ischemic and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosed</span> limbs have in the past been attributed to allergic vasospastic reactions. Whether these are in fact identical to the <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>-associated complications remains to be determined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bb4bd509-82a8-423c-96d4-e583d098f6f1"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">Miscellaneous</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> following long-term administration of high doses of heparin, cutaneous <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> after systemic administration, suppression of aldosterone synthesis, delayed transient <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and rebound <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span> on discontinuation of heparin sodium have also been reported.</p>
<p>Significant elevations of aminotransferase (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> [S-AST] and SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_eb78cbd0-9a62-481b-93ee-dcd0288f953c"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a0b259a6-d779-4e49-8100-41467bccf51c"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">Symptoms</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> is the chief sign of heparin overdosage. <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Nosebleeds</span>, <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood in urine</span> or <span class="product-label-link" type="condition" conceptid="4103703" conceptname="Melena">tarry stools</span> may be noted as the first sign of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or petechial formations may precede frank <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_637fbda4-c9a6-439b-af77-4c0dec75d779"></a><a name="section-9.2"></a><p></p>
<h2><span class="Bold">Treatment</span></h2>
<p class="First">Neutralization of heparin effect.</p>
<p>When clinical circumstances (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. <span class="Bold">No more than 50 mg</span> should be administered, <span class="Bold">very slowly</span>, in any 10-minute period. Each mg of protamine sulfate neutralizes approximately 100 USP heparin units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection.</p>
<p>Administration of protamine sulfate can cause severe hypotensive and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. Because fatal reactions often resembling <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported, the drug should be given only when resuscitation techniques and treatment of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid shock</span> are readily available.</p>
<p>For additional information consult the labeling of Protamine Sulfate Injection, USP products.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_e4e432a4-ed5a-4762-97a2-36a6e0a8699f"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First"><span class="Bold">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Slight discoloration does not alter potency.</span></p>
<p><span class="Bold">Confirm the choice of the correct Heparin Sodium Injection vial prior to administration of the drug to a patient. (See </span><span class="Bold"><a href="#LINK_3f23bc81-ce92-4e17-80f2-c6c113b91dab">WARNINGS, Fatal Medication Errors</a></span><span class="Bold">.)</span> The 1 mL vial must not be <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confused</span> with a â€œcatheter lock flushâ€? vial or other 1 mL vial of inappropriate strength. To lessen this risk, the 1 mL vial includes a red cautionary label that extends above the main label. Read the cautionary statement and confirm that you have selected the correct medication and strength. Then locate the â€œTear Hereâ€? point on the label, and remove this red cautionary label prior to removing the flip-off cap.</p>
<p>When heparin is added to an infusion solution for continuous intravenous administration, the container should be inverted at least six times to ensure adequate mixing and prevent pooling of the heparin in the solution.</p>
<p>Heparin sodium is not effective by oral administration and should be given by intermittent intravenous injection, intravenous infusion, or deep subcutaneous (intrafat, i.e., above the iliac crest or abdominal fat layer) injection. <span class="Bold">The intramuscular route of administration should be avoided because of the frequent occurrence of <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> at the injection site.</span></p>
<p>The dosage of heparin sodium should be adjusted according to the patientâ€™s coagulation test results. When heparin is given by continuous intravenous infusion, the coagulation time should be determined approximately every 4 hours in the early stages of treatment. When the drug is administered intermittently by intravenous injection, coagulation tests should be performed before each injection during the early stages of treatment and at appropriate intervals thereafter. Dosage is considered adequate when the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (APTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value. After deep subcutaneous (intrafat) injections, tests for adequacy of dosage are best performed on samples drawn 4 to 6 hours after the injection.</p>
<p>Periodic platelet counts, hematocrits and tests for occult <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">blood in stool</span> are recommended during the entire course of heparin therapy, regardless of the route of administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d3dea8a7-bf2e-47ef-a962-c6146d6ec7d6"></a><a name="section-10.1"></a><p></p>
<h2><span class="Bold">Converting to Oral Anticoagulant</span></h2>
<p class="First">When an oral anticoagulant of the coumarin or similar type is to be begun in patients already receiving heparin sodium, baseline and subsequent tests of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity must be determined at a time when heparin activity is too low to affect the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This is about 5 hours after the last intravenous bolus and 24 hours after the last subcutaneous dose. If continuous IV heparin infusion is used, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time can usually be measured at any time.</p>
<p>In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant should be the usual initial amount and thereafter <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time should be determined at the usual intervals. To ensure continuous anticoagulation, it is advisable to continue full heparin therapy for several days after the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time has reached the therapeutic range. Heparin therapy may then be discontinued without tapering.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7edca8d1-6b91-4d85-9642-8e936947458e"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold">Therapeutic Anticoagulant Effect With Full-Dose Heparin</span></h2>
<p class="First">Although dosage must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines:</p>
<table>
<col>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="top"><p class="First">METHOD OF<br>ADMINISTRATION</p></td>
<td class="Botrule Toprule" align="center" valign="top">Â FREQUENCY</td>
<td class="Botrule Toprule" align="center" valign="top">Â RECOMMENDED DOSE<br>[based on 150 lb (68 kg) patient]</td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top">Deep Subcutaneous (Intrafat) Injection</td>
<td align="center" valign="top">Â Initial dose<br>
</td>
<td valign="top"><p class="First">5,000Â units by IV injection, followed by 10,000 to 20,000Â units of a concentrated solution, subcutaneously</p></td>
</tr>
<tr>
<td valign="top">A different site should be used for each injection to prevent the development of massive <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span></td>
<td align="center" valign="top"><p class="First">Â Every 8 hours<br><br>or</p></td>
<td valign="top">8,000 to 10,000Â units of a concentrated solution</td>
</tr>
<tr>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â Every 12 hours</td>
<td valign="top"><p class="First">15,000 to 20,000Â units of a concentrated solution</p></td>
</tr>
<tr>
<td class="Toprule" valign="top">Intermittent Intravenous Injection</td>
<td class="Toprule" align="center" valign="top">Â Initial dose</td>
<td class="Toprule" valign="top"><p class="First">10,000 units, either undiluted or in 50 to 100Â mL of 0.9% Sodium Chloride Injection, USP</p></td>
</tr>
<tr>
<td align="center" valign="top">Â </td>
<td align="center" valign="top">Â Every 4 to 6 hours</td>
<td valign="top"><p class="First">5,000 to 10,000Â units, either undiluted or in 50 to 100Â mL of 0.9% Sodium Chloride Injection, USP</p></td>
</tr>
<tr>
<td class="Toprule" valign="top">Intravenous Infusion<br>
</td>
<td class="Toprule" align="center" valign="top">Â Initial dose<br>
</td>
<td class="Toprule" valign="top">5,000 units by IV injection</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" valign="top">Â </td>
<td class="Botrule" align="center" valign="top">Â Continuous</td>
<td class="Botrule" valign="top"><p class="First">20,000 to 40,000Â units/24 hours in 1000Â mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_41e85100-eb03-4c8c-bb85-a30d127829b6"></a><a name="section-10.3"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Use preservative-free Heparin Sodium Injection in neonates and infants (seeÂ <span class="Bold"><a href="#LINK_a5b360e6-b4e5-4af0-950e-3e5404f6aa1e">WARNINGS, Benzyl Alcohol Toxicity</a></span> and <span class="Bold"><a href="#LINK_45320c83-be87-4768-a06b-a02fead70db7">PRECAUTIONS, Pediatric Use</a></span>).</p>
<p>There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. In general, the following dosage schedule may be used as a guideline in pediatric patients:</p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top"><p class="First">Initial DoseÂ </p></td>
<td valign="top"><p class="First">75 to 100 units/kg (IV bolus over 10 minutes)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Maintenance Dose</p></td>
<td valign="top">
<p class="First">Infants: 25 to 30 units/kg/hour;<br>Â Â Â Â Infants &lt; 2 months have the highest requirments (average 28 units/kg/hour)</p>
<p>Children &gt; 1 year of age: 18 to 20 units/kg/hour;<br>Â Â Â Â Older children may require less heparin, similar to weight-adjusted adult dosage</p>
</td>
</tr>
<tr class="Last">
<td valign="top"><p class="First">Monitoring</p></td>
<td valign="top"><p class="First">Adjust heparin to maintain APTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d1599f1c-828f-4984-9769-10907e5af30a"></a><a name="section-10.4"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Patients over 60 years of age may require lower doses of heparin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84ba08bb-3e1d-4812-a963-eaabe7c377e1"></a><a name="section-10.5"></a><p></p>
<h2><span class="Bold">Surgery of the Heart and Blood Vessels</span></h2>
<p class="First">Patients undergoing total body perfusion for open-heart surgery should receive an initial dose of not less than 150 units of heparin sodium per kilogram of body weight. Frequently, a dose of 300 units per kilogram is used for procedures estimated to last less than 60 minutes, or 400 units per kilogram for those estimated to last longer than 60 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_84c4e4b8-d1d3-4263-b76e-ac4c3a4c9a79"></a><a name="section-10.6"></a><p></p>
<h2><span class="Bold">Low-Dose Prophylaxis of Postoperative <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></span></h2>
<p class="First">A number of well-controlled clinical trials have demonstrated that low-dose heparin prophylaxis, given just prior to and after surgery, will reduce the incidence of postoperative <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in the legs (as measured by the I-125 fibrinogen technique and venography) and of clinical <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>. The most widely used dosage has been 5,000 units 2 hours before surgery and 5,000 units every 8 to 12 hours thereafter for 7 days or until the patient is fully ambulatory, whichever is longer. The heparin is given by deep subcutaneous injection in the arm or abdomen with a fine needle (25- to 26-gauge) to minimize tissue <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>. A concentrated solution of heparin sodium is recommended. Such prophylaxis should be reserved for patients over the age of 40 who are undergoing major surgery. Patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders and those having neurosurgery, spinal anesthesia, eye surgery or potentially sanguineous operations should be excluded, as should patients receiving oral anticoagulants or platelet-active drugs (see <span class="Bold"><a href="#LINK_e5d281db-df71-4928-b910-51e0983dade8">WARNINGS</a></span>). The value of such prophylaxis in hip surgery has not been established. The possibility of increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during surgery or postoperatively should be borne in mind. If such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs, discontinuance of heparin and neutralization with protamine sulfate are advisable. If clinical evidence of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> develops despite low-dose prophylaxis, full therapeutic doses of anticoagulants should be given unless contraindicated. All patients should be screened prior to heparinization to rule out <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders, and monitoring should be performed with appropriate coagulation tests just prior to surgery. Coagulation test values should be normal or only slightly elevated. There is usually no need for daily monitoring of the effect of low-dose heparin in patients with normal coagulation parameters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8c74f915-5e5b-458a-8436-209ea3c5fee4"></a><a name="section-10.7"></a><p></p>
<h2><span class="Bold">Extracorporeal Dialysis</span></h2>
<p class="First">Follow equipment manufacturersâ€™ operating directions carefully.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a6fd971d-2b58-4fd2-8129-ce478a134d83"></a><a name="section-10.8"></a><p></p>
<h2><span class="Bold">Blood Transfusion</span></h2>
<p class="First">Addition of 400 to 600 USP units per 100 mL of whole blood is usually employed to prevent coagulation. Usually, 7,500 USP units of heparin sodium are added to 100 mL of 0.9% Sodium Chloride Injection, USP (or 75,000 USP units per 1000 mL of 0.9% Sodium Chloride Injection, USP) and mixed; from this sterile solution, 6 to 8 mL are added per 100 mL of whole blood.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4bc30d8e-93d0-4d05-989c-bd5ffdf212b9"></a><a name="section-10.9"></a><p></p>
<h2><span class="Bold">Laboratory Samples</span></h2>
<p class="First">Addition of 70 to 150 units of heparin sodium per 10 to 20 mL sample of whole blood is usually employed to prevent coagulation of the sample. Leukocyte counts should be performed on heparinized blood within 2 hours after addition of the heparin. Heparinized blood should not be used for isoagglutinin, complement, or erythrocyte fragility tests or platelet counts.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_c1c3c8ef-32d1-44af-8bc1-5d788d5dc098"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Heparin Sodium Injection, USP</p>
<p>1,000 USP units/mL<br>Â Â Â Â 1 mL vial packaged in 25s (NDC 0641-0391-12)<br>Â Â Â Â 30 mL Multiple Dose vial packaged in 25s (NDC 0641-2450-55)</p>
<p>5,000 USP units/mL<br>Â Â Â Â 1 mL vial packaged in 25s (NDC 0641-0400-12)<br>Â Â Â Â 10 mL Multiple Dose vial packaged in 25s (NDC 0641-2460-55)</p>
<p>10,000 USP units/mL<br>Â Â Â Â 1 mL vial packaged in 25s (NDC 0641-0410-12)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="LINK_1f677dc8-16de-408a-b644-ff38b217c183"></a><a name="section-11.1"></a><p></p>
<h2><span class="Bold">Storage</span></h2>
<p class="First"><span class="Bold">Store at 20Â°-25Â°C (68Â°-77Â°F) [See USP Controlled Room Temperature].</span></p>
<p>To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or <a href="#medwatch">www.fda.gov/medwatch</a>.</p>
<p>For Product Inquiry call 1-877-845-0689.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_371eac49-58a8-43b2-bc80-c040b6f36c46"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol class="Arabic">
<li>Tahata T, Shigehito M, Kusuhara K, Ueda Y, et al. Delayed-Onset of Heparin Induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> â€“ A Case Report â€“ <span class="Italics">J Jpn Assn Torca Surg</span>.1992;40(3):110-111.
</li>
<li>Warkentin T, Kelton J. Delayed-Onset <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-Induced Thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>. <span class="Italics">Annals of Internal Medicine</span>, 2001;135:502-506.
</li>
<li>Rice L, Attisha W, Drexler A, Francis J. Delayed-Onset Heparin Induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>. <span class="Italics">Annals of Internal Medicine</span>, 2002;136:210-215.
</li>
<li>Dieck J., C. Rizo-Patron, et al. (1990). â€œA New Manifestation and Treatment Alternative for Heparin-Induced <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>.â€? Chest.1990;98:1524-26.
</li>
<li>Smythe M, Stephens J, Mattson. Delayed-Onset Heparin Induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>. <span class="Italics">Annals of Emergency Medicine</span>, 2005;45(4):417-419.
</li>
<li>Divgi A. (Reprint), Thumma S., Hari P., Friedman K., Delayed Onset <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-Induced Thrombocytopenia</span> (HIT) Presenting After Undocumented Drug Exposure as Post-Angiography <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>. <span class="Italics">Blood</span>. 2003;102(11):127b.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_85bce149-b4f3-4f4c-9b90-667fda339f1c"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br><img alt="West-Ward Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7014808d-cec9-4b2c-8eb5-940493e356ab&amp;name=heparin-sodium-injection-usp-2.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
<p><span class="Bold">WEST-WARD<br></span>PHARMACEUTICALS<span class="Bold"><br></span>Eatontown, NJ 07724 USA</p>
<p>Revised September 2011</p>
<p>462-274-11</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_6900803c-5a12-4b18-a72a-6f2ee443e4f1"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Heparin Sodium Injection, USP<br>1,000 USP units/mL<br>25 x 1 mL Vial<br><span class="Bold">NDC </span>0641-0391-12</p>
<div class="Figure">
<img alt="Heparin Sodium Injection, USP 1,000 USP units/mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7014808d-cec9-4b2c-8eb5-940493e356ab&amp;name=heparin-sodium-injection-usp-3.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_e8b51464-989f-40b4-9871-8295d5e5a194"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Heparin Sodium Injection, USP<br>5,000 USP units/mL<br>25 X 1 mL Vials<br>NDC 0641-0400-12</p>
<p>Â <img alt="Heparin Sodium Injection, USP 5,000 USP units/mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7014808d-cec9-4b2c-8eb5-940493e356ab&amp;name=heparin-sodium-injection-usp-4.jpg"><p class="MultiMediaCaptionNotCentered"></p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_62fa0d35-0289-47b3-8e96-6bc976d77ac6"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Heparin Sodium Injection, USP<br>10,000 USP units/mL<br>25 x 1 mL<br>NDC 0641-0410-12</p>
<div class="Figure">
<img alt="Heparin Sodium Injection, USP 10,000 USP units/mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7014808d-cec9-4b2c-8eb5-940493e356ab&amp;name=heparin-sodium-injection-usp-5.jpg"><p class="MultiMediaCaption"></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEPARIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">heparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-0391</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HEPARIN SODIUM</strong> (HEPARIN) </td>
<td class="formItem">HEPARIN SODIUM</td>
<td class="formItem">1000Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.6Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.01Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0391-12</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0391-37</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017037</td>
<td class="formItem">03/22/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEPARIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">heparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-2450</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HEPARIN SODIUM</strong> (HEPARIN) </td>
<td class="formItem">HEPARIN SODIUM</td>
<td class="formItem">1000Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">8.6Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.01Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-2450-55</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-2450-30</td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017037</td>
<td class="formItem">03/22/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEPARIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">heparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-0400</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HEPARIN SODIUM</strong> (HEPARIN) </td>
<td class="formItem">HEPARIN SODIUM</td>
<td class="formItem">5000Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.01Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0400-12</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0400-37</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017037</td>
<td class="formItem">03/22/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEPARIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">heparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-2460</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HEPARIN SODIUM</strong> (HEPARIN) </td>
<td class="formItem">HEPARIN SODIUM</td>
<td class="formItem">5000Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.01Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-2460-55</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-2460-30</td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017037</td>
<td class="formItem">03/22/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HEPARIN SODIUMÂ 		
					</strong><br><span class="contentTableReg">heparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0641-0410</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HEPARIN SODIUM</strong> (HEPARIN) </td>
<td class="formItem">HEPARIN SODIUM</td>
<td class="formItem">10000Â [USP'U] Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">0.01Â mL Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0410-12</td>
<td class="formItem">25  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0641-0410-37</td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017037</td>
<td class="formItem">03/22/1972</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-ward Pharmaceutical Corp.
							(946499746)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">West-ward Pharmaceutical Corp</td>
<td class="formItem"></td>
<td class="formItem">946499746</td>
<td class="formItem">ANALYSIS(0641-0391, 0641-2450, 0641-0400, 0641-0410, 0641-2460), LABEL(0641-0391, 0641-2450, 0641-0400, 0641-0410, 0641-2460), MANUFACTURE(0641-0391, 0641-2450, 0641-0400, 0641-2460, 0641-0410)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>598491a0-a026-4212-babf-3fbb4230ca38</div>
<div>Set id: 7014808d-cec9-4b2c-8eb5-940493e356ab</div>
<div>Version: 6</div>
<div>Effective Time: 20120110</div>
</div>
</div>Â <div class="DistributorName">West-ward Pharmaceutical Corp.</div></p>
</body></html>
